There is a completely different perspective email today from [email protected] about Viraleze being “nasal hygiene” no mention of covid, which parallels the description of Nasodine in its US launch this month. Is the new direction a strategy to launch without seeking FDA approval in the US and compete with Nasodine. Two Australian products with greater efficacy than Paxlovid but great for all respiratory viruses - which have been given terrible treatment in Australia - their country of origin.
There is a completely different perspective email today from...
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $47.38M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 12.0¢ | 11.5¢ | $10.85K | 94.31K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 88755 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 203344 | 11 |
View Market Depth
| Last trade - 13.31pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
11.5¢ |
Change
0.000 ( 0.00 %) |
||||
| Open | High | Low | Volume | ||
| 11.5¢ | 11.8¢ | 11.5¢ | 29472 | ||
| Last updated 13.27pm 21/05/2024 ? | |||||
| SPL (ASX) Chart |